Twist Bioscience (NASDAQ:TWST) CEO Sells $46,962.24 in Stock

Key Points

• Twist Bioscience CEO Emily Leproust sold 1,704 shares for a total of $46,962.24, reducing her ownership stake by 0.27% to 633,036 shares.
• The company's stock is currently valued at $27.02, having decreased by 2.2%, with a market cap of $1.63 billion and a PE ratio of -18.63.
• Twist Bioscience recently reported quarterly earnings with an EPS of ( -$0.47), surpassing analyst expectations and generating revenue of $96.06 million.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CEO Emily Leproust sold 1,704 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $27.56, for a total transaction of $46,962.24. Following the sale, the chief executive officer directly owned 633,036 shares of the company's stock, valued at approximately $17,446,472.16. This trade represents a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Twist Bioscience Trading Down 2.2%

Shares of Twist Bioscience stock traded down $0.62 during trading hours on Wednesday, hitting $27.02. The company's stock had a trading volume of 1,294,335 shares, compared to its average volume of 1,237,755. Twist Bioscience Corporation has a 12 month low of $24.07 and a 12 month high of $55.33. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. The stock has a 50 day moving average of $29.09 and a 200 day moving average of $33.63. The company has a market capitalization of $1.63 billion, a PE ratio of -18.63 and a beta of 2.31.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. The business had revenue of $96.06 million for the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Institutional Investors Weigh In On Twist Bioscience

A number of hedge funds have recently made changes to their positions in TWST. Cetera Investment Advisers acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $220,000. Nuveen Asset Management LLC lifted its holdings in Twist Bioscience by 43.8% during the 4th quarter. Nuveen Asset Management LLC now owns 292,645 shares of the company's stock worth $13,599,000 after buying an additional 89,170 shares during the period. GF Fund Management CO. LTD. bought a new position in Twist Bioscience during the 4th quarter worth approximately $58,000. Versant Capital Management Inc raised its holdings in Twist Bioscience by 547.2% during the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock worth $27,000 after purchasing an additional 580 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in Twist Bioscience by 6,499.1% during the 1st quarter. GAMMA Investing LLC now owns 29,366 shares of the company's stock worth $1,153,000 after purchasing an additional 28,921 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have recently commented on TWST shares. Evercore ISI set a $46.00 price objective on shares of Twist Bioscience in a research report on Monday, August 4th. Cowen reissued a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $49.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.